A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α

Por Horton, Holly M., Anderson, Deborah, Hernandez, Pepe, Barnhart, Kerry M., Norman, Jon A., Parker, Suezanne E.
Publicado em 1999

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

Por Friedman, Kevin M., Garrett, Tracy E., Evans, John W., Horton, Holly M., Latimer, Howard J., Seidel, Stacie L., Horvath, Christopher J., Morgan, Richard A.
Publicado no Hum Gene Ther (2018)

Enhanced antibody half-life improves in vivo activity

Por Zalevsky, Jonathan, Chamberlain, Aaron K., Horton, Holly M., Karki, Sher, Leung, Irene W.L., Sproule, Thomas J., Lazar, Greg A., Roopenian, Derry C., Desjarlais, John R.
Publicado em 2010

A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity

Por Garrett, Tracy E, Chekmasova, Alena A, Evans, John W, Seidel, Stacie L, Horton, Holly M, Latimer, Howard J, Griecci, Johanna A, Horvath, Christopher J, Ryu, Byoung Y, Friedman, Kevin M, Morgan, Richard A
Publicado no J Immunother Cancer (2015)

Immune suppression in cynomolgus monkeys by XPro9523: An improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn

Por Bernett, Matthew J., Chu, Seung Y., Leung, Irene, Moore, Gregory L., Lee, Sung-Hyung, Pong, Erik, Chen, Hsing, Phung, Sheryl, Muchhal, Umesh S., Horton, Holly M., Lazar, Greg A., Desjarlais, John R, Szymkowski, David E.
Publicado em 2013

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

Por Tai, Yu-Tzu, Horton, Holly M., Kong, Sun-Young, Pong, Erik, Chen, Hsing, Cemerski, Saso, Bernett, Matthew J., Nguyen, Duc-Hanh T., Karki, Sher, Chu, Seung Y., Lazar, Greg A., Munshi, Nikhil C., Desjarlais, John R., Anderson, Kenneth C., Muchhal, Umesh S.
Publicado em 2012